Every Oral GLP-1 Medication Available in 2026: The Complete Guide

1. Wegovy Pill — Available Now

The first oral GLP-1 medication approved specifically for weight loss. FDA-approved December 22, 2025; launched January 2026. Uses Novo Nordisk’s SNAC permeation enhancer technology to deliver semaglutide through the stomach lining.

Weight loss: Approximately 15% body weight in clinical trials, comparable to injectable Wegovy 2.4mg. Key limitation: Requires daily dosing on an empty stomach with a 30-minute fast afterward. Even a cup of coffee breaks the protocol and reduces absorption. Best for: Patients who want an FDA-approved oral option right now and can commit to the morning fasting routine.

2. Ozempic Tablets — Available Q2 2026

Formerly Rybelsus. Oral semaglutide approved for type 2 diabetes, rebranded under the Ozempic name in February 2026. Available doses: 3mg, 7mg, and 14mg daily.

Key distinction from Wegovy pill: Approved for diabetes, not weight loss. Maximum dose (14mg) is lower than the Wegovy pill (50mg). Some physicians prescribe it off-label for weight loss, but the lower dose range means less weight loss compared to the Wegovy pill. Best for: Patients with type 2 diabetes who want oral semaglutide. Off-label weight loss use may be considered when insurance covers the diabetes indication but not weight loss.

3. Orforglipron — Expected Approval April 2026

Eli Lilly’s oral small-molecule GLP-1 agonist. PDUFA date April 10, 2026. If approved, expected market launch Q2–Q3 2026. The first oral GLP-1 that doesn’t require fasting or special administration.

Weight loss: 12.4% at 36 weeks in ATTAIN-1. Longer-duration data expected to show additional loss. Game-changer factor: Take it any time, with or without food. No water restrictions. No 30-minute wait. The simplest oral GLP-1 administration of any product on the market. Cannot be compounded: Proprietary small-molecule structure means no compounding alternative will exist. Best for: Patients who want maximum convenience, dislike needles and fasting protocols, or want an alternative to semaglutide.

4. Aleniglipron — Phase 3 Starting Mid-2026

Structure Therapeutics’ oral small-molecule GLP-1 agonist. Phase 2 results showed 15.3% weight loss at the 240mg dose — competitive with semaglutide injection results. Phase 3 trials expected to begin mid-2026, with potential FDA approval in 2028 at the earliest.

Why it matters: The Phase 2 data is among the strongest for any oral GLP-1 candidate. If Phase 3 confirms these results, aleniglipron could offer semaglutide-level weight loss in a no-fasting pill. Best for: Not yet available — one to watch for patients considering future options.

5. Danuglipron — Earlier Stage

Pfizer’s oral GLP-1 candidate. Phase 2 data has been less consistent than competitors, and Pfizer has adjusted its development strategy. Currently in a reformulated once-daily version after earlier twice-daily dosing showed tolerability challenges.

Pfizer has also invested heavily in PF-3944, a monthly injectable GLP-1 with 10 Phase 3 trials running in 2026. The company’s GLP-1 strategy spans both oral and injectable approaches.

What About Compounded Oral Semaglutide?

Some compounding pharmacies offer semaglutide in sublingual (under-the-tongue) drops or troches. These are fundamentally different from the Wegovy pill or Ozempic tablets for one critical reason: they lack SNAC technology.

Without SNAC, semaglutide’s oral bioavailability is extremely low. The approved oral formulations use SNAC to achieve 0.4–1% absorption through the stomach lining. Sublingual absorption of large peptides through the oral mucosa is even less efficient. While some patients report results from compounded sublingual semaglutide, the pharmacological consistency is far inferior to injectable or SNAC-enabled oral delivery.

Our recommendation: if you want oral semaglutide, the Wegovy pill provides a vastly more reliable and clinically validated option than compounded sublingual formulations. If you prefer compounded semaglutide, stick with the injectable form where absorption is well-characterized.

The Oral GLP-1 Future

The oral GLP-1 market is evolving from a single option (Rybelsus, approved 2019 for diabetes only) to a competitive landscape with multiple products, multiple manufacturers, and multiple approaches to oral delivery. By the end of 2026, patients could have three FDA-approved oral GLP-1 medications available, with at least two more in late-stage development.

This competition will likely drive prices down, improve access, and reduce dependence on compounded alternatives. For patients who are currently using compounded injectable semaglutide primarily because of cost, the oral options represent a credible path to FDA-approved therapy at comparable or lower prices.

The era of “inject or nothing” is over. 2026 is the year GLP-1 medications became pills.